This is a working overview of Copper peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-01 and is reviewed periodically as new material appears.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
=== Sales === There are currently 6,157 total Domino's units in the United States, and of those 5,815 of those are franchised units. In 2018, the Average Weekly Unit Sales (AWUS) for franchised units was $22,045, showing a consistent increase over the past five years. Per year, this amounts to an average of over a million dollars in sales. Domino's EBITDA was 15.0% for stores making more than $25,000. The vast majority of stores fell under this category, more than 1,500 units. According to Domino's 2019 income statement, their net income was just over $400,000. The initial franchise fee for a Domino's franchise is $10,000, the royalty fee is 5.5% of the store's weekly sales, and the advertising payment is 4% of the store's weekly sales.
== History == Ubrogepant, also known as MK-1602, was discovered by scientists at Merck in 2020. The effectiveness of ubrogepant for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials. In these studies, 1,439 adult patients with a history of migraine, with and without aura, received the approved doses of ubrogepant to treat an ongoing migraine. In both studies, the percentages of patients achieving pain relief two hours after treatment (defined as a reduction in headache severity from moderate or severe pain to no pain) and whose most bothersome migraine symptom (nausea, light sensitivity or sound sensitivity) stopped two hours after treatment were significantly greater among patients receiving ubrogepant (19–21% depending on the dose) compared to those receiving placebo (12%). Patients were allowed to take their usual acute treatment of migraine at least two hours after taking ubrogepant. 23% of patients were taking a preventive medication for migraine. In December 2019, the US Food and Drug Administration approved Ubrelvy produced by Allergan USA, Inc. for treatment of migraine after onset.
Side effects are generally similar to other antipsychotics. The drug has a relatively well tolerated side effect profile, with low propensity for QTc interval changes, weight gain and lipid-related adverse effects. In a 2013 meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs, it was found to produce the second least (after haloperidol) weight gain, the least QT interval prolongation, the fourth most extrapyramidal side effects (after haloperidol, zotepine and chlorpromazine), and the sixth least sedation (after paliperidone, sertindole, amisulpride, iloperidone and aripiprazole). As with other atypical neuroleptics, lurasidone should be used with caution in the elderly because it puts them at an increased risk for a stroke or transient ischemic attack; however, these risks are not likely to be greater than those associated with antipsychotics of other classes. Similarly, lurasidone should not be used to treat dementia-related psychosis, as evidence has shown increased mortality with antipsychotic use. Weight gain is reported in up to 15 and 16 percent of users. Other possible side effects include vomiting, akathisia, dystonia, parkinsonism, somnolence, dizziness, sedation and nausea.
Sources: en.wikipedia.org
== Regulation == Thyroxine has a half-life of approximately one week and hence maintains relatively stable blood levels. Its production and release are controlled through a complex feedback loop involving the hypothalamus, pituitary gland, and thyroid gland. This regulatory system ensures that optimal hormone levels are maintained.
== Santos syndrome == Santos syndrome is characterized by short stature, fibular agenesis or hypoplasia, clubfeet with oligodactyly, acromial dimples, limited forearm/hand range of motion, and severe nail hypoplasia or anonychia. It is caused by a homozygous mutation in the WNT7A gene, leading to a phenotype similar to Fuhrmann syndrome but with preaxial polydactyly and less severe limb defects. The inheritance pattern is autosomal dominant with incomplete penetrance. This mutation has a recent origin (73 years) and is located inside a Native-american homozygous haplotype. It was discovered by Silvana Santos, a Brazilian researcher who won the 100 Woman BBC prize in 2024.
=== Video games === In April 2026, Austin was revealed to be added to Fortnite. He is the sixth WWE outfit added to the game following -- John Cena, Becky Lynch, Bianca Belair, Cody Rhodes and The Undertaker. Dwayne Johnson appears in the game but not as himself or The Rock but in an acting role using his likeness for the character The Foundation.
Sources: en.wikipedia.org
== Further reading == Beardsley, E. (2006). "The Spartanburg Pellagra Hospital". The South Carolina Encyclopedia. Columbia, South Carolina: University of South Carolina Press. ISBN 1-57003-598-9. Crabb, Mary Katherine (1992). "An Epidemic of Pride: Pellagra and the Culture of the American South". Anthropologica. 34 (1): 89–103. doi:10.2307/25605634. JSTOR 25605634. Hampl, J. S.; Hampl, W. S. (1 November 1997). "Pellagra and the origin of a myth: evidence from European literature and folklore". Journal of the Royal Society of Medicine. 90 (11): 636–39. doi:10.1177/014107689709001114. PMC 1296679. PMID 9496281. Hendrick, Burton J. (April 1916). "The Mastery of Pellagra: The Mysterious Disease, Almost Unknown in This Country Fifteen Years Ago, That Now Claims 7,500 Victims A Year And Is Spreading Rapidly". The World's Work: A History of Our Time. XXXI: 633–39. Kraut, Alan (3 September 2010). "Dr. Joseph Goldberger and the War on Pellagra". Office of NIH History. National Institutes of Health. Archived from the original on 22 October 2004. "Reports and Resolutions of the General Assembly of the State of South Carolina, Regular Session Commencing January 11, 1916". Annual Report of the State Board of Health (1915–1916). 4. Columbia, South Carolina: Gonzales and Bryan, state printers. 1916. Swain, C. P.; Tavill, A. S.; Neale, G. (September 1976). "Studies of tryptophan and albumin metabolism in a patient with carcinoid syndrome, pellagra, and hypoproteinemia". Gastroenterology. 71 (3): 484–89. doi:10.1016/s0016-5085(76)80460-x. PMID 133045.
=== Proteomics === Screens for biologically relevant protein-protein interactions have been performed using Tandem Affinity Purification (TAP) with the SBP-Tag and Protein A, for interaction proteomics and transcription factor complexes with the SBP-Tag and Protein G, for proteins that interact with the Dengue Virus protein DENV-2 NS4A with the SBP-Tag and the Calmodulin Tag. and for proteins that interact with protein phosphatase 2A (PP2A) with the SBP-Tag and the hemagglutinin (HA)-tag.
Bivalves and the gastropods in the family Juliidae have very similar shells. There are limpet-like forms in several lines of gastropods: "true" limpets, pulmonate siphonariid limpets and several lineages of pulmonate freshwater limpets. Cephalopod (like in octopuses and squid) and vertebrate eyes are both lens-camera eyes with much overall similarity, yet are very unrelated species. A closer examination reveals some differences including embryonic development, extraocular muscles, number of lens parts, and the lack of a retinal blindspot in the cephalopod eye. Swim bladders: buoyant bladders independently evolved in fishes, the tuberculate pelagic octopus, and siphonophores such as the Portuguese man o' war. Bivalves and brachiopods independently evolved paired hinged shells for protection. However, the anatomy of their soft parts is very dissimilar, which is why molluscs and brachiopods are put into different phyla. Jet propulsion in squids and in scallops: these two groups of mollusks have very different ways of squeezing water through their bodies in order to power rapid movement through a fluid. (Dragonfly larvae in the aquatic stage also use an anal jet to propel them, and jellyfish have used jet propulsion for a very long time.) Sea hares (gastropod molluscs) employ a similar means of jet propulsion, but without the sophisticated neurological machinery of cephalopods they navigate somewhat more clumsily. Tunicates (such as salps), and some jellyfish also employ jet propulsion.
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
Inductively coupled plasma mass spectrometry or atomic absorption spectroscopy gives total copper after acid digestion. Combining that value with a peptide concentration from chromatography or amino acid analysis yields the metal-to-peptide ratio.